Holen Sie sich die Stockscreener-App
3.72
0.81%
0.03
Handel nachbörslich:
3.53
-0.19
-5.11%
Schlusskurs vom Vortag:
$3.69
Offen:
$3.79
24-Stunden-Volumen:
255.56K
Relative Volume:
0.28
Marktkapitalisierung:
$421.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.86M
KGV:
-0.2317
EPS:
-16.054
Netto-Cashflow:
$-17.68M
1W Leistung:
+83.70%
1M Leistung:
+133.96%
6M Leistung:
+68.33%
1J Leistung:
+1,092%
1-Tages-Spanne:
$3.41
$3.85
1-Wochen-Bereich:
$2.17
$4.1699
52-Wochen-Spanne:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Firmenname
Indaptus Therapeutics Inc
Sektor
Branche
Telefon
(646) 427-2727
Adresse
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
3.72 | 417.86M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks
Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
INDP Q4 2025 Earnings: EPS Misses Estimates Amid No Revenue; Stock Surges Over 114%Revenue Beat Analysis - newsline.com
INDP - Finviz
INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com
Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli
Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
Indaptus Therapeutics Reports Q1 2026 Financial Results, Management Changes, and Strategic Review Amid Cash Constraints - Minichart
Indaptus Therapeutics reassesses decoy platform as cash dwindles - grafa.com
Indaptus Therapeutics Q1 Financial Analysis - Intellectia AI
Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway - Stock Titan
Cash drops at Indaptus (Nasdaq: INDP) as Q1 2026 loss narrows - Stock Titan
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 net loss narrows as expenses fall - TradingView
Press Release: Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
INDP Should I Buy - Intellectia AI
TradingKey - TradingKey
INDP | Indaptus Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q1'26 Earnings: EPS estimate is (1.87) USD - TradingView
Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan
Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - newser.com
Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser
Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart
Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan
Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks
Indaptus Therapeutics appoints two new independent directors and announces board changes By Investing.com - Investing.com South Africa
Indaptus Therapeutics appoints two new independent directors and announces board changes - Investing.com
Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns - TradingView
Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan
Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20 - newsline.com
Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18Trend Analysis - Xã Châu Thành
Sino Lion Ventures Ltd Net Worth (2026) - GuruFocus
Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):